176 related articles for article (PubMed ID: 18485135)
1. Viability of developing CETP inhibitors.
Sirtori CR; Mombelli G
Cardiovasc Ther; 2008; 26(2):135-46. PubMed ID: 18485135
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Neeli H; Rader DJ
Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
[TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
4. The potential for CETP inhibition to reduce cardiovascular disease risk.
Ansell B; Hobbs FD
Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
[TBL] [Abstract][Full Text] [Related]
5. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
6. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
[TBL] [Abstract][Full Text] [Related]
7. Is high HDL cholesterol always good?
Olsson AG
Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter P
Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
[TBL] [Abstract][Full Text] [Related]
9. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
10. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
11. CETP inhibition in cardiovascular risk management: a critical appraisal.
Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Vergeer M; Stroes ES
Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942
[TBL] [Abstract][Full Text] [Related]
13. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
Zhao L; Jin W; Rader D; Packard C; Feuerstein G
Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
[TBL] [Abstract][Full Text] [Related]
14. Structural and biophysical insight into cholesteryl ester-transfer protein.
Hall J; Qiu X
Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
16. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Kontush A; Guérin M; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein (CETP) inhibitors.
Hunt JA; Lu Z
Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458
[TBL] [Abstract][Full Text] [Related]
20. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
Regieli JJ; Jukema JW; Grobbee DE; Kastelein JJ; Kuivenhoven JA; Zwinderman AH; van der Graaf Y; Bots ML; Doevendans PA
Eur Heart J; 2008 Nov; 29(22):2792-9. PubMed ID: 18957472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
